Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Axovant Sciences Ltd (AXGT)

Axovant Sciences Ltd (AXGT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 123,245
  • Shares Outstanding, K 22,781
  • Annual Sales, $ 0 K
  • Annual Income, $ -129,070 K
  • 60-Month Beta 1.24
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.00
  • Number of Estimates 4
  • High Estimate -0.68
  • Low Estimate -1.33
  • Prior Year -2.16
  • Growth Rate Est. (year over year) +53.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.18 +0.97%
on 10/21/19
6.93 -24.53%
on 11/04/19
-0.49 (-8.57%)
since 10/11/19
3-Month
5.18 +0.97%
on 10/21/19
8.08 -35.27%
on 09/17/19
-1.34 (-20.40%)
since 08/12/19
52-Week
3.81 +37.27%
on 06/11/19
19.60 -73.32%
on 03/11/19
-10.37 (-66.47%)
since 11/12/18

Most Recent Stories

More News
Axovant (AXGT) Upgraded to Buy: Here's What You Should Know

Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AXGT : 5.23 (-3.33%)
Axovant (AXGT) Gains As Market Dips: What You Should Know

In the latest trading session, Axovant (AXGT) closed at $6.61, marking a +0.46% move from the previous day.

AXGT : 5.23 (-3.33%)
Axovant (AXGT) Stock Moves -1.31%: What You Should Know

Axovant (AXGT) closed at $7.53 in the latest trading session, marking a -1.31% move from the prior day.

AXGT : 5.23 (-3.33%)
Axovant (AXGT) Gains As Market Dips: What You Should Know

Axovant (AXGT) closed at $7.69 in the latest trading session, marking a +0.92% move from the prior day.

AXGT : 5.23 (-3.33%)
Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2

Immunomedics (IMMU) posts wider-than-expected loss and generates no revenues in the second quarter of 2019.

EPZM : 15.03 (+1.18%)
ACOR : 1.98 (-9.59%)
IMMU : 17.40 (+1.16%)
AXGT : 5.23 (-3.33%)
Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates

Horizon (HZNP) beats earnings and sales estimates in the second quarter of 2019.

EPZM : 15.03 (+1.18%)
HZNP : 30.23 (+0.73%)
ACOR : 1.98 (-9.59%)
AXGT : 5.23 (-3.33%)
Catalyst's (CPRX) Q2 Earnings and Revenues Beat Estimates

Catalyst (CPRX) surpasses earnings and sales estimates in the second quarter of 2019.

EPZM : 15.03 (+1.18%)
ACOR : 1.98 (-9.59%)
CPRX : 4.91 (-2.19%)
AXGT : 5.23 (-3.33%)
Geron (GERN) Stock Up Despite Q2 Earnings & Sales Miss

Geron (GERN) posts a wider-than-expected loss in second-quarter 2019. Operating expenses increase on a year-over-year basis.

JNJ : 131.35 (-0.48%)
ACOR : 1.98 (-9.59%)
GERN : 1.44 (-2.70%)
AXGT : 5.23 (-3.33%)
IVERIC bio's (ISEE) Q2 Loss Narrows, Gene Therapy in Focus

IVERIC bio (ISEE) second-quarter earnings improve year over year. The company is focusing on developing gene therapies for treating inherited retinal diseases.

ALXN : 109.44 (+0.39%)
ACOR : 1.98 (-9.59%)
ISEE : 3.20 (-5.88%)
AXGT : 5.23 (-3.33%)
Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down

Clovis (CLVS) reports dismal second-quarter 2019 results. The company provides lower-than-expected guidance for product sales in 2019.

BMY : 58.39 (+0.41%)
CLVS : 5.47 (+1.67%)
ALKS : 19.90 (+0.13%)
AXGT : 5.23 (-3.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade AXGT with:

Business Summary

Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease...

See More

Key Turning Points

2nd Resistance Point 5.46
1st Resistance Point 5.35
Last Price 5.23
1st Support Level 5.16
2nd Support Level 5.08

See More

52-Week High 19.60
Fibonacci 61.8% 13.57
Fibonacci 50% 11.70
Fibonacci 38.2% 9.84
Last Price 5.23
52-Week Low 3.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar